The debate on costs of pharmaceutical distribution is often affected by ideological premises (public versus private) when empirical data should be more important. The article analyses a case of pharmaceutical distribution operated by a public healthcare organization, considering activities, costs and results. The article analyses strength and weakness points of the different solutions available in the case and shows that when public healthcare organisation and private external distributors act in partnership it is possible to achieve the best results, both on the side of quality and on the side of costs. The analysis offers an example of the different factors that influence the level of costs; shows the importance of economic evaluations and points out that efficiency is not related to the nature (public or private) of the distributing subject.
Keywords: Pharmaceutical distribution, costs, public private partnership.